Ipsen’s Group Strategy

Focus. Together. For patients & society. Ipsen’s new Group strategy explained

David Loew, CEO IpsenFive months ago, I joined Ipsen as CEO. I was excited to join a company with 90 years of patient service and consistent growth, and a clear mission, to prolong and improve patients’ lives and health outcomes.

Today, I have the pleasure of kicking off a new chapter in this long history of success. Following a thorough review of what makes us thrive and where we can improve, working closely together with the Executive Leadership Team and many more colleagues across the globe, we are presenting a new Group strategy for Ipsen.

In the coming years, we will build on our strong foundation of engaged employees, agile development capabilities and global commercial footprint to drive positive impact for patients, our people and our business. Our new Group strategy positions Ipsen for long-term success and can be summed up quite simply: Focus. Together. For patients & society.

Focus: A clear sense of prioritization will drive our activities. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience – areas where we have proven experience and global capabilities along with a strong network of partners. We will focus on maximizing our existing brands and strengthen and accelerate our external innovation efforts in clearly-defined segments, leveraging €3Bn in firepower over the next four years to replenish our innovative pipeline.

Together: Our employees are the hearts, brains and architects of our success. Our experienced, global team will work together to boost a culture of collaboration, patient-centricity and innovation, and we will hone our operational excellence to continue to be an employer of choice for highly engaged talent. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline.

For patients & society: We will deliver innovative treatments that make a real difference in patients’ daily lives and partner with the entire healthcare ecosystem to ensure they have access to them. By concentrating on the right priorities, we will create sustainable, long-term growth and positive impact for all stakeholders and most importantly for patients and society.

We’ve defined four strategic priorities to achieve these ambitious goals: bring the full potential of our innovative medicines to patients; build a high-value sustainable pipeline; deliver efficiencies to enable targeted investment & growth; boost culture of collaboration and excellence.

With this new strategy concentrating on the right priorities, I am confident we will realize our vision of being a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in oncology, rare disease and neuroscience.

The next chapter in Ipsen’s storied history begins today – and I look forward to making it a reality in collaboration with our 5,700+ Ipsen colleagues and numerous partners across the world.

Group strategy

Bring the full potential of our innovative medicines to patients

Build a high-value sustainable pipeline

Deliver efficiencies to enable targeted & growth

Boost culture of collaboration & excellence

4 strategic priorities

Our CBO Philippe Lopes-Fernandes tells @PharmaBoardroom about our approach to partnering and plans for building a robust pipeline and for speeding up patients’ access to innovation. #Partnering #ForPatientsandSociety

As part of our commitment to the Primary Biliary Cholangitis ( #PBC) community, Ipsen will remain focused on raising awareness about this debilitating disease. Early diagnosis is critical to ensuring proper treatment and care.

As part of our new partnership with @genfit_pharma, we’re excited to learn from the #PBC community. This disease can be debilitating, so we’re proud to be advancing #research and developing new investigational therapies for people living with rare conditions around the world.

Primary Biliary Cholangitis ( #PBC) is a rare progressive liver disease that can have harmful effects. At Ipsen, we are committed to identifying and advancing innovative solutions for people living with #rarediseases like PBC.

As the #KidneyCancer landscape evolves, it’s key to understand the importance of quality of life and how this can influence and personalize long-term patient care.

Watch more from the experts in a recent panel discussion with @ecancer.

Ipsen is honored to be collaborating with @genfit_pharma uniting our collective expertise to develop therapies for people living with Primary Biliary Cholangitis ( #PBC). We have ambitious goals and they’re the right partner to help bring our goals to life.
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022